The partners plan to investigate whether a woman’s response to ovarian stimulation during IVF treatment is linked to genomic characteristics.
Although the two studies seem to provide conflicting results on the impact of PGS, the "devil's in the details," according to an outside expert.
In response to public comment on draft recommendations published last year, the USPSTF changed course and retained cotesting as an option.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The firm is working on harnessing its ability to assess fetal fraction to develop new methods to predict fetal aneuploidy risks and pregnancy complications.
Clinical research has shown that the assay exhibited 100 percent sensitivity compared to culture-based testing methods, Hologic said.
Myriad said that it will fund the $375 million acquisition with a combination of cash, common stock, and funds from its revolving credit facility.
A team of researchers in Japan used a noninvasive prenatal testing platform to detect copy number alterations in about 20 percent of gynecological cancers they tested.
Researchers sequenced mothers who experienced preterm birth and found a possible role for steroid signaling in birth timing.
The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.
Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.
Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.
Researchers from Stanford University reported in a pilot study that seven RNA transcripts could predict preterm birth.
The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.
The firm said it would likely do a joint submission of its ctDNA assay to the FDA and CMS for approval and a national coverage determination.
The DOJ alleged Biotheranosics promoted and performed its Breast Cancer Index test for patients who had not been in remission for five years and who had not been taking tamoxifen.
The ResistancePlus MG Positive Control kit was listed with the FDA for sale in the US, where it will be sold through SpeeDx's US entity.
The firm also offers an NIPT, codeveloped with Yale, that its CEO said is differentiated by its rapid time-to-result.
A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.
Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.
In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.